24 completed, 9 terminated, 4 active not recruiting, 4 recruiting. 22 Phase 2, 17 Phase 1, 3 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow ceritinib: new trials by email Literature Review of ceritinib trials Research Report on ceritinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceritinib Treatment for Recurrent Meningiomas Ceritinib - Recurrent Meningioma, Grade I and Grade II | Phase 2 | Not yet recruiting | Kevin Petrecca | 10 | 2027-01-01 | 2026-10-23 |
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| Improving Public Cancer Care by Implementing Precision Medicine in Norway Atezolizumab - Cancer Metastatic | Phase 2 | Recruiting | Oslo University Hospital | 3000 | 2021-04-01 | 2024-02-29 |
| Antineoplastic Drugs in Elderly Patients Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs) - Cancer | Recruiting | Shandong University | 500 | 2021-01-01 | 2022-07-20 | |
| Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. crizotinib, alectinib, brigatinib - ALK-positive NSCLC | Completed | Pfizer | 549 | 2020-12-14 | 2023-04-06 | |
| PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study PD-1 inhibitor, Chemotherapy Drugs, Cancer - Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events | Unknown | Sungkyunkwan University | 4724 | 2020-07-01 | 2020-05-28 | |
| Molecular Profiling of Advanced Soft-tissue Sarcomas Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 603 | 2019-10-19 | 2026-04-29 |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Alectinib, Brigatinib, Carboplatin - Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2019-07-25 | 2026-04-23 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Ceritinib, Docetaxel - Non-small Cell Lung Cancer, Lung Cancer | Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 21 | 2019-02-01 | 2026-05-15 |
| A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement LDK378(Ceritinib) - Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | Phase 2 | Unknown | Yonsei University | 46 | 2018-07-24 | 2019-01-11 |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors Brigatinib, Alectinib, Ceritinib - Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung | Completed | Takeda | 111 | 2018-07-23 | 2024-07-15 | |
| Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma Ceritinib, Trametinib - Melanoma, Unresectable Melanoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2018-06-27 | 2026-02-27 |
| Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis - Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present | Phase 1 / Phase 2 | Withdrawn | University of Washington | 2018-01-03 | 2019-10-10 | |
| Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Ceritinib, Trametinib - Non-small Cell Lung Cancer | Phase 1 | Terminated | University of California, San Francisco | 9 | 2017-09-09 | 2022-12-27 |
| Next Generation Personalized Neuroblastoma Therapy Biopsy, Next Generation Sequencing, Tumor Scans - Neuroblastoma, Cancer | Phase 1 | Terminated | Yael P Mosse | 66 | 2016-07-01 | 2026-03-10 |
| Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer Ceritinib, Everolimus, Laboratory Biomarker Analysis - ALK Positive, Locally Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 37 | 2016-06-22 | 2026-05-20 |
| Ceritinib Rare Indications Study in ALK+ Tumors Ceritinib (LDK378) - Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Novartis Pharmaceuticals | 22 | 2016-05-06 | 2019-12-27 |
| Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis ceritinib 750mg - Glioblastoma, Brain Metastases | Early Phase 1 | Completed | St. Joseph's Hospital and Medical Center, Phoenix | 10 | 2016-02-17 | 2020-12-11 |
| Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study ceritinib - ALK Positive Malignancies | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 233 | 2015-12-11 | 2026-09-17 |
Showing 20 of 49. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (20) · Lung Neoplasms (7) · Adenocarcinoma of Lung (5) · Neoplasms (5) · Lymphoma, Large-Cell, Anaplastic (4) · Brain Neoplasms (3) · Granuloma, Plasma Cell (3) · Hematologic Neoplasms (3) · Neoplasm Metastasis (3) · Neuroblastoma (3) · Cholangiocarcinoma (2) · Glioblastoma (2) · Melanoma (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma (1)
Novartis Pharmaceuticals (22) · H. Lee Moffitt Cancer Center and Research Institute (2) · Pfizer (2) · University of California, San Francisco (2) · University of Texas Southwestern Medical Center (2) · Yonsei University (2) · Anne Beaven, MD (1) · Criterium, Inc. (1) · Giselle Sholler (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Kevin Petrecca (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · National Health Research Institutes, Taiwan (1) · Oslo University Hospital (1)
United States (31) · Italy (14) · South Korea (14) · Spain (14) · Canada (11) · France (10) · Australia (9) · Singapore (9) · Germany (8) · United Kingdom (8) · Belgium (7) · Hong Kong (7) · Japan (7) · Netherlands (7) · Taiwan (7)
Adil Daud (1) · Andreas Saltos, M.D. (1) · Andrei Shustov (1) · Anne Beaven, MD (1) · Antoine Italiano (1) · Christopher Lieu, MD (1) · Collin Blakely, MD, PhD (1) · George R Blumenschein (1) · Giselle Sholler, MD (1) · Jessica J Lin (1) · John M Maris, MD (1) · Ju-Young Shin, PhD (1) · Nader Sanai, MD (1)
PMID 27130468, PMID 24670165, PMID 26020125, PMID 26337354, PMID 26973324, PMID 27432917, PMID 27565932, PMID 28126333, PMID 28369553, PMID 28602779, PMID 29474558, PMID 29518553, PMID 29959809, PMID 30697903, PMID 31778798, PMID 32713836, PMID 34740331, PMID 34780709, PMID 34890832, PMID 35091443, PMID 35568909, PMID 36545322
2014 (3), 2017 (1), P30CA015704 (1), U10CA180868 (1)